Skip to Content

Bicalutamide Dosage

Medically reviewed on March 27, 2017.

Applies to the following strengths: 50 mg

Usual Adult Dose for Prostate Cancer

50 mg orally once a day, given at the same time each day.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild hepatic impairment: No adjustment recommended
Moderate to severe hepatic impairment: Caution is advised due to possible increased accumulation of bicalutamide.


Bicalutamide should be used with caution in patients with moderate to severe hepatic impairment. Bicalutamide is extensively metabolized by the liver. Limited data in subjects with severe hepatic impairment suggest that excretion of bicalutamide may be delayed and could lead to further accumulation. Periodic liver function tests should be considered for patients on long-term therapy.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Bicalutamide is not dialyzable.

Other Comments

For treating prostate cancer, luteinizing hormone-releasing hormone (LHRH) analog therapy should be started at the same time as treatment with bicalutamide. Regular assessments of serum prostate specific antigen (PSA) may be helpful in monitoring patient response. For patients who have evidence of progression of disease together with an elevated PSA, a treatment-free period of antiandrogen, while continuing the LHRH analog, may be considered. The dose of bicalutamide when used for any other malignant disease may depend upon the specific indication for its use and whether other cytotoxic agents are coadministered.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.